Mimedx (MDXG) Return on Sales (2011 - 2026)

Mimedx (MDXG) posted Return on Sales of 0.0% for Q2 2026, down 25.24% sequentially from 0.0% in Q1 2026, and little changed YoY from 0.0% in Q2 2025.

Mimedx (MDXG) Return on Sales (2011 - 2026) Analysis & Trends

Mimedx has reported Return on Sales for 16 years, with the latest figure at 0.0% in Q2 2026.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.0% (changed 0.0% YoY) and the FY2024 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales fell to 0.0% in Q2 2026 per MDXG's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.0% in Q4 2022 and troughed at 0.0% in Q2 2026.
A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 0 bps in 2022, down 0 bps in 2022.
Over 5 years, Return on Sales stood at 0.0% in 2022, then plunged by 81 bps to 0.0% in 2023, then sank by 95 bps to 0.0% in 2024, then slumped by 51 bps to 0.0% in 2025, then slumped by 38752 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q2 2026, Q1 2026, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	0.00%

Download Data